# Defeatbeta Analyst > Professional financial analysis using 60+ market data APIs. Use for: company fundamentals (revenue, margins, EPS, balance sheet), valuation (P/E, P/B, P/S, PEG, DCF, intrinsic value), profitability (ROE, ROA, ROIC), growth trends (YoY revenue/earnings/FCF), earnings transcripts (key data, changes, guidance), industry benchmarking, segment/geography revenue breakdown, business model analysis, competitive landscape, risk analysis, investment thesis, bull/bear scenarios. Trigger on: stock tickers, company names, financial metrics, or any investment research request. DO NOT trigger for: general economics, non-public companies, crypto/commodities with no equity ticker. - Skill: `defeat-beta/defeatbeta-analyst` (Agent Skill, multi-file: 3 files) - Install (CLI): `npx skillmds@latest add defeat-beta/defeatbeta-analyst` - Raw SKILL.md: https://api.skillmd.com/api/skills/defeat-beta/defeatbeta-analyst/raw - Safety review: pending - Works with: Claude Code, Claude.ai, OpenAI Codex - Category: Marketing & Growth - Author: defeat-beta (https://skillmd.com/u/defeat-beta) - Updated: 2026-09-17 - Page: https://skillmd.com/skills/defeat-beta/defeatbeta-analyst --- # Financial Analyst Professional-grade financial analysis using historical market data and comprehensive financial metrics from the [defeatbeta dataset](https://huggingface.co/datasets/defeatbeta/yahoo-finance-data). ## Defaults Unless the user specifies otherwise: - **Always call `get_latest_data_update_date` first** — this is "today" for all relative time queries - **Default analysis**: When given only a ticker (e.g., `/defeatbeta-analyst AAPL`), run **Template 1: Quick Investment Screening** - **ROIC and Equity Multiplier**: Not applicable to banks/financial institutions — check `sector` in profile first - **Date format**: "YYYY-MM-DD" - **Data limits**: Price/valuation APIs return max 1000 rows — use date ranges for large datasets ## Template Selection Choose the template that best matches the user's request. Read [analysis-templates.md](./references/analysis-templates.md) for the full workflow of any template. | User request | Template | |-----------------------------------------------|----------------------------------------------------| | Quick check / "should I look at this stock?" | T1: Quick Investment Screening | | Full company deep-dive | T2: Full Fundamental Analysis | | Overvalued / undervalued / P/E / P/B / DCF | T3: Valuation-Focused or T10: DCF Valuation | | Revenue growth / earnings quality / ROIC | T4: Growth Quality Assessment | | ROE decomposition / DuPont | T5: DuPont Analysis | | Margin trends / vs peers | T6: Margin Analysis & Peer Comparison | | Accruals / FCF quality / working capital | T7: Earnings Quality Assessment | | Industry positioning | T8: Industry Positioning Analysis | | Latest earnings release numbers | T9: Quarterly Earnings Analysis | | "What did management report this quarter?" | T11: Extract Key Financial Data from Earnings Call | | "What changed vs last quarter/year?" | T12: Financial Metric Changes from Earnings Call | | "What is management's guidance/outlook?" | T13: Financial Metric Forecasts from Earnings Call | | "What does this company do?" / business model | T14: Business Understanding | | Revenue segments / geography breakdown | T15: Revenue Breakdown | | Industry trends / tailwinds / headwinds | T16: Industry Context | | Competitors / moat / pricing power | T17: Competitive Landscape | | Balance sheet strength / debt / FCF quality | T18: Financial Quality | | Risks / downside / what could go wrong | T19: Risks and Downside | | Management track record / capital allocation | T20: Management and Execution | | Bull case / bear case / scenarios | T21: Bull and Bear Scenarios | | How to value / valuation assumptions | T22: Valuation Framework | | Long-term thesis / why invest / must go right | T23: Long-Term Investment Thesis | ## API Gotchas **REQUIRED**: Before calling any API, read the relevant section in [defeatbeta-api-reference.md](./references/defeatbeta-api-reference.md) to confirm the correct parameters and response schema. 1. **Fiscal periods**: Earnings transcripts use fiscal periods (may differ from calendar) — specify both `fiscal_year` and `fiscal_quarter` 2. **SEC filing access**: Must use `sec_user_agent` field value as User-Agent header when accessing SEC URLs (SEC blocks without it) ## Rendering Financial Statements When displaying results from `get_stock_*_income_statement`, `get_stock_*_balance_sheet`, or `get_stock_*_cash_flow`, you MUST follow these rules. The response contains a `statement` array where each row has `label`, `indent`, `is_section`, and `values` fields. **Rules:** 1. **Preserve row order** — never reorder, skip, or merge rows 2. **Indent** — prefix each label with `indent × 2` spaces (`indent=0` → no prefix, `indent=1` → 2 spaces, `indent=2` → 4 spaces, etc.) 3. **is_section=true** — render the label in **bold**; this row is a section header and the rows immediately below it (with `indent = this.indent + 1`) are its children 4. **is_section=false** — render the label in normal weight 5. **values[i]** corresponds to `periods[i]`; `null` means data not available 6. **Do NOT add calculated rows** (e.g. margin %) that are not present in the data **Example — given these rows:** | label | indent | is_section | |-------------------|--------|------------| | Total Revenue | 0 | true | | Operating Revenue | 1 | false | | Cost of Revenue | 0 | false | | Operating Expense | 0 | true | | SG&A | 1 | false | | R&D | 1 | false | **Correct rendered output:** | Item | 2025Q4 | 2025Q3 | |-------------------------------|--------|--------| | **Total Revenue** | 10,270 | 9,246 | |   Operating Revenue | 10,270 | 9,246 | | Cost of Revenue | 4,693 | 4,466 | | **Operating Expense** | 3,825 | 3,510 | |   SG&A | 1,198 | 1,069 | |   R&D | 2,330 | 2,139 | ## Reference Documentation **Detailed step-by-step workflows (T1–T23)** → [analysis-templates.md](./references/analysis-templates.md) **API parameters, response schemas, examples (60+ APIs)** → [defeatbeta-api-reference.md](./references/defeatbeta-api-reference.md)